The study analyzes therapeutic innovations derived from snake venom through a review of patents filed from 2014 to 2024. China remains the leader in the field, followed by South Korea, Japan, and the United States. Interest in these molecules is growing steadily due to their many biological activities: anticoagulant, anticancer, anti-inflammatory, analgesic, and antimicrobial. The most widely used snake families are Elapidae and Viperidae, whose venoms exhibit an extraordinary variety of toxins with clinical applications. Major therapeutic areas include cancer, pain, inflammation, coagulation diseases, and infections. However, technical and economic challenges persist in the purification, stabilization, and delivery of these compounds. The study concludes by highlighting the future potential of snake venom in modern pharmacology, with the prospect of new therapies through the use of advanced technologies.
Lo studio analizza le innovazioni terapeutiche derivate dal veleno di serpente attraverso una revisione dei brevetti depositati dal 2014 al 2024. La Cina si conferma leader nel settore, seguita da Corea del Sud, Giappone e Stati Uniti. L’interesse verso queste molecole è in costante crescita, grazie alle loro numerose attività biologiche: anticoagulanti, antitumorali, antinfiammatorie, analgesiche e antimicrobiche. Le famiglie di serpenti più utilizzate sono Elapidae e Viperidae, i cui veleni mostrano una straordinaria varietà di tossine con applicazioni cliniche. Le principali aree terapeutiche includono cancro, dolore, infiammazione, malattie della coagulazione e infezioni. Tuttavia, persistono sfide tecniche ed economiche nella purificazione, stabilizzazione e somministrazione di questi composti. Lo studio conclude sottolineando il potenziale futuro del veleno di serpente nella farmacologia moderna, con la prospettiva di nuove terapie grazie all’uso di tecnologie avanzate.
INNOVAZIONI NELLA TERAPIA DERIVATA DAL VELENO DI SERPENTE
CECCHINI, ALESSIA
2024/2025
Abstract
The study analyzes therapeutic innovations derived from snake venom through a review of patents filed from 2014 to 2024. China remains the leader in the field, followed by South Korea, Japan, and the United States. Interest in these molecules is growing steadily due to their many biological activities: anticoagulant, anticancer, anti-inflammatory, analgesic, and antimicrobial. The most widely used snake families are Elapidae and Viperidae, whose venoms exhibit an extraordinary variety of toxins with clinical applications. Major therapeutic areas include cancer, pain, inflammation, coagulation diseases, and infections. However, technical and economic challenges persist in the purification, stabilization, and delivery of these compounds. The study concludes by highlighting the future potential of snake venom in modern pharmacology, with the prospect of new therapies through the use of advanced technologies.| File | Dimensione | Formato | |
|---|---|---|---|
|
TESI E FRONTESPIZIO NON FIRMATO.pdf
accesso aperto
Dimensione
1.77 MB
Formato
Adobe PDF
|
1.77 MB | Adobe PDF | Visualizza/Apri |
I documenti in UNITESI sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/20.500.12075/22526